Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trialNeuro-oncology 2022 Jul 15;[EPub Ahead of Print], AB Lassman, SL Pugh, TJC Wang, K Aldape, HK Gan, M Preusser, MA Vogelbaum, EP Sulman, M Won, P Zhang, G Moazami, MS Macsai, MR Gilbert, EE Bain, V Blot, PJ Ansell, S Samanta, MG Kundu, TS Armstrong, JS Wefel, C Seidel, FY de Vos, S Hsu, AF Cardona, G Lombardi, D Bentsion, RA Peterson, C Gedye, V Bourg, A Wick, WJ Curran, MP Mehta
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.